Christopher H. Yaen

Associate
Christopher Yaen counsels clients on patent prosecution and enforcement in a variety of technical areas, including chemical, life science, agricultural, and mechanical arts.
Christopher Yaen, Associate at Arent Fox

Client Work

Christopher represents clients before the United States Patent and trademark Office (USPTO) in ex parte prosecution and contested cases before the Patent and Trial Appeal Board (PTAB), including inter partes re‐examination, inter partes review (IPR), and interference proceedings. He drafts and prosecutes US and international patent applications. Christopher performs patent due diligence for purposes of investment, mergers, and acquisitions.

Some of Christopher’s representative matters include:

  • Served as back‐up counsel in an interference appeal before the U.S. Court of Appeals for the Federal Circuit for a medical device company.
  • Represented a biopharmaceutical company in patent matters for an $110 million IPO.
  • Represented a pharmaceutical company in an inter partes re‐examination before the PTAB relating to small molecule pharmaceuticals.
  • Represented a medical device company in an IPR before the PTAB relating to wound dressings.
  • Represented a Fortune 500 company in an IPR before the PTAB relating to agricultural products.
  • Represented a biotechnology company in an ex parte re‐examination relating to recombinantly engineered plant parts.
  • Conducted due diligence for Fortune 10 company in the acquisition of a molecular diagnostics company.
  • Represented a Fortune 10 company in a licensing agreement relating to diagnostic materials.
  • Represented a biotech company in patent matters relating to a merger in the field of monoclonal antibody technology.
  • Represented a foreign research institute in negotiating royalty terms of a licensing agreement
  • Serves as lead and backup counsel in inter partes review proceedings before the Patent Trial and Appeal Board.

Previous Work

Prior to joining Arent Fox, Christopher was an associate at Hunton & Williams. He also served as a Primary Patent Examiner in the United States Patent and Trademark Office, where he examined patent applications relating to cancer immunology, including antibodies, peptides, small molecules, cellular immunotherapies, methods of treating cancer, diagnosing cancer, constructing antibodies, and producing agents for treating cancer.

Professional Activities

Christopher is a member of the American Intellectual Property Law Association.

Publications, Presentations & Recognitions

Christopher’s recent articles and publications include:

  • Ferber A., Yaen C., Martinez J., (2002) An octapeptide in the juxtamembrane domain of VE‐cadherin is important for p120ctn binding and cell proliferation. Exp Cell Res., 274(1):35‐44.
  • Martinez J., Ferber A., Bach T., Yaen C., (2001) Interaction of fibrin with VE‐cadherin. Ann. N.Y. Acad. Sci., 936:386‐405.
  • Yaen C., Song M., Ferber A., and Martinez J., (2000) Role of vascular endothelial cadherin extracellular domain one in cell‐cell associations. Blood, 96(11):174.
  • Ferber A., Yaen C., Martinez J., (1999) An eight amino acid sequence in the cytoplasmic juxtamembrane region of VE‐cadherin is important for the p120ctn binding and cellular proliferation. Blood, 94(621a).
  • Yaen C.H., Bach T.L., Ferber A., Martinez J. (1999) The interaction of the N‐terminal domain of fibrin with a mutant form of VE‐cadherin in the formation of capillary tubes. Thromb. Haemo., 82(2a):207.
  • Kioka N., Sakata S., Kawauchi T., Amachi T., Akiyama S.K., Okazaki K., Yaen C., Yamada K.M., Aota S., (1999)
  • Vinexin: A novel vinculin‐binding protein with multiple SH3 domains enhances actin cytoskeletal organization. J. Cell Biol., 144(1):59‐69.
  • Grant D.S., Rose W., Yaen C., Goldstein A., Martinez J., Kleinman, H., (1999) Thymosin B4 enhances cell differentiation and angiogenesis. Angiogenesis, 3:125‐135.
  • Yaen C.H., Bach T.L., Ferber A., Martinez J. (1998) The interaction of the N‐terminal domain of fibrin with VEcadherin. Blood Supplement American Society of Hematology Meeting.
  • Bach, T.L., Barsigian, C., Yaen C.H., Martinez, J. (1998) Endothelial cell VE‐cadherin functions as a receptor for the 15‐42 sequence of fibrin. J. Biol. Chem., 273 (46): 30719‐30728.
  • Bach, T.L., Barsigian, C., Chalpupowicz, D.G., Busler D., Yaen, C.H., Grant D., Martinez, J. (1998) VE‐Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp. Cell. Research, 238:324‐334.

Christopher’s speaking engagements include:

  • Twenty‐Eighth Annual Philadelphia Workshop on Hemostasis, Thrombosis, and Atherosclerosis, November 2000, Role of vascular endothelial cadherin extracellular domain 1 in cell‐cell associations.
  • Twenty‐Seventh Congress of the International Society for Thrombosis and Hemostasis, August 1999, The interaction of the N‐Terminal domain of fibrin with a mutant form of VE‐Cadherin in the formation of capillary tubes.
  • Twenty‐Sixth Annual Philadelphia Workshop on Hemostasis, Thrombosis, and Atherosclerosis, November 1998, Role of the interaction of the N‐terminal domain of fibrin with VE‐Cadherin in the formation of capillary tubes.
  • The Third Annual Philadelphia Cadherin Club, October 1998, The role of VE‐Cadherin in the formation of capillary like‐structures.
  • Industries
  • Bar & Court Admissions
    • District of Columbia Bar
    • US Patent and Trademark Office Bar
    • US Court of Appeals, Federal Circuit
  • Education
    Georgetown Law
    JD
    2010
    Thomas Jefferson University
    PA
    Master of Science in Biomedical Chemistry
    2001
    University of Maryland
    BS
    Bachelor of Science in Neurobiology and Physiology
    1996